Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial Meeting Abstract
| Authors: | Richardson, P. G.; Jacobus, S. J.; Weller, E.; Hassoun, H.; Lonial, S.; Raje, N. S.; Medvedova, E.; McCarthy, P. L.; Libby, E. N.; Voorhees, P. M.; Orlowski, R. Z.; Anderson, L. D. Jr; Hurd, D. D.; Pasquini, M. C.; Masone, K.; Moreau, P.; Avet-Loiseau, H.; Attal, M.; Anderson, K. C.; Munshi, N. C. |
| Abstract Title: | Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-10 |
| Language: | English |
| ACCESSION: | WOS:000891791500005 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.17_suppl.LBA4 |
| Notes: | Meeting Abstract: LBA4 -- Source: Wos |
